{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-24-000040","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.863283+00:00","generated_at":"2026-06-03T11:33:32.641236+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ImmunityBio gets FDA approval for ANKTIVA in BCG-unresponsive NMIBC; CR rate 62%, DOR >47 months","bullets":["FDA approved ANKTIVA (N-803) plus BCG for BCG-unresponsive NMIBC with CIS on April 22, 2024.","Complete response rate of 62% in evaluable patients; duration of complete response >47 months and ongoing.","58% of patients had DOR ≥12 months, 40% had DOR ≥24 months; median DOR not yet reached.","ANKTIVA expected to be available in U.S. by mid-May 2024; conference call April 26 at 11am EDT.","Company plans to seek approval to increase shares under 2015 Equity Incentive Plan by up to 19.9M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-24-000040","json":"https://secwatch.observer/filing/0001326110-24-000040.json","markdown":"https://secwatch.observer/filing/0001326110-24-000040.md","text":"https://secwatch.observer/filing/0001326110-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000040/0001326110-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000040/ibrx-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:33:32.641236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}